At the news
? BEARISHIMPACT 5/10 8-K filed Nov 9, 2026 at 16:08 ET
Zentalis reported Q3 2026 net loss of $28.8M ($0.34 per share), narrower than the $0.52 consensus estimate, with cash of $228.9M providing runway into 1H 2028. The DENALI Part 2 topline readout was pushed to 1H 2027 (from year-end 2026), and management plans to discuss accelerated approval with the FDA in 2027, signaling a delay in the regulatory timeline.
- Q3 2026 net loss $28.8M ($0.34/share) vs consensus $-0.52, beat on EPS
- Cash $228.9M as of Sep 30, 2026, including $86.9M net from Aug 2026 follow-on offering of 26.45M shares
- DENALI Part 2 topline readout delayed from year-end 2026 to 1H 2027
- Management plans to discuss DENALI data with FDA in 2027 to assess accelerated approval opportunity
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access